Investigadores del IDIS descubren una nueva terapia dirigida contra el cáncer anaplásico de tiroides sin dañar células sanas

El trabajo identifica un agente terapéutico que elimina de forma selectiva las células cancerosas anaplásicas de tiroides, uno de los cánceres más agresivos y devastadores para el que, en la actualidad, existen pocas opciones efectivas de tratamiento

The scientific director of the Health Research Institute of Santiago de Compostela (IDIS), Mª Luz Couce Pico, receives the XXIII Nóvoa Santos Award

The Association of Galician Doctors distinguishes the work of the scientific director of IDIS as the greatest exponent of Galician neonatology.

DIVERSA Biotechnologies has concluded its capital expansion with Sémola Tech Ventures SL, Volsunga SL, Janus Projects SL, and UNIRISCO.

The spin-off of the Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) and SERGAS, specialized in nanomedicine, aims to have an impact on the development of innovative drugs, specifically in the areas of oncology and rare diseases, but also in many others due to its collaborative business model.

News

Calendar

Load More

COMMON SUPPORT PLATFORMS

The platforms are research support units featured by a high strategic value, equipped by cutting edge technologies and operated by highly specialised technical staff.

CALLS

All updated information on public and private competitive calls. The most convenient and safest way to send your requests.

CAREERS

Would you like to join our team? We are always looking for people with a passion for research and propelled by insatiable curiosity to join our mission of providing a better healthcare day every day. Here you can see and apply for our current vacancies.

Research Areas

ONCOLOGY

Improvement of treatments: personalised therapy and reduction of side effects.

GENETICS AND SYSTEMS BIOLOGY

Identification of genetic biomarkers of disease susceptibility and prognosis

ENDOCRINOLOGÍA, NUTRICIÓN Y METABOLISMO

The area studies obesity from different perspectives with the participation of groups from the clinical and basic fields in a synergistic way.

NEUROSCIENCES

Search for new therapeutic targets and improvement of the clinical-therapeutic management of neurological patients, mainly stroke, Alzheimer’s, Parkinson’s disease, headaches and neurological diseases caused by prions.

CARDIOVASCULAR

The general objective of the Cardiovascular Area consists of the search for new therapeutic targets and the improvement of clinical-therapeutic management.

PLATFORMS AND METODOLOGY

The area aims at providing evidence for prioritising the management of public resources, evaluating risks and identifying opportunities for improving the health of the population. From here, prioritise structural investments and action programs.